Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft Vs. Host Disease (COMPLETED) - Full Text View

Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft Vs. Host Disease (COMPLETED)

This study has been completed.

Sponsored by:	Schering-Plough
Information provided by:	Schering-Plough
ClinicalTrials.gov Identifier:	NCT00034645

Purpose

This trial is in high risk patients to determine the safety, tolerance and efficacy of posaconazole (POZ) vs. fluconazole in the prophylaxis against development of invasive fungal infections (IFI).

Condition	Intervention	Phase
Mycoses	Drug: Posaconazole oral suspension	Phase III

MedlinePlus related topics:

Fungal Infections

Drug Information available for:

Posaconazole

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by Schering-Plough:

Estimated Enrollment:	600
Study Start Date:	February 1998
Estimated Study Completion Date:	December 2003

Detailed Description:

This study is designed to determine the safety, tolerance and efficacy of POZ used as prophylaxis of IFI in high-risk subjects with Grade II-IV acute graft vs. host disease (GVHD) or extensive chronic GVHD. The primary objective is to assess the efficacy of SCH56592 vs fluconazole in preventing proven or probable IFI within the time period from randomization to 16 weeks after the start of treatment with study drug.

Eligibility

Ages Eligible for Study:	13 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Hematopoietic progenitor cell transplant subjects with chronic or Grade II-IV acute GVHD being treated with high dose immunosuppressive therapy.
One of the following to the subject's prior immunosuppressive regimen:
1. at least 1mg per kg per day of methylprednisolone or equivalent,
2. Antithymocyte globulin (ATG) for the therapy of acute GVHD,
3. Tacrolimus, mycophenolate mofetil, or other steroid-sparing immunosuppressive regimen.

Contacts and Locations

No Contacts or Locations Provided

More Information

Publications indexed to this study:

Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007 Jan 25;356(4):335-47.

Study ID Numbers:	C/I98-316
First Received:	May 1, 2002
Last Updated:	May 31, 2006
ClinicalTrials.gov Identifier:	NCT00034645
Health Authority:	United States: Food and Drug Administration

Keywords provided by Schering-Plough:

Allogenic Stem cell transplantation

Fungal infections

Study placed in the following topic categories:

Mycoses

Clotrimazole

Graft versus host disease

Miconazole

Tioconazole

Graft vs Host Disease

Posaconazole

Homologous wasting disease

Additional relevant MeSH terms:

Trypanocidal Agents

Anti-Infective Agents

Antiparasitic Agents

Antiprotozoal Agents

Therapeutic Uses

Antifungal Agents

Antibiotics, Antifungal

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 30, 2008